Literature DB >> 24937141

X-chromosome inactivation in development and cancer.

Ronan Chaligné1, Edith Heard2.   

Abstract

X-chromosome inactivation represents an epigenetics paradigm and a powerful model system of facultative heterochromatin formation triggered by a non-coding RNA, Xist, during development. Once established, the inactive state of the Xi is highly stable in somatic cells, thanks to a combination of chromatin associated proteins, DNA methylation and nuclear organization. However, sporadic reactivation of X-linked genes has been reported during ageing and in transformed cells and disappearance of the Barr body is frequently observed in cancer cells. In this review we summarise current knowledge on the epigenetic changes that accompany X inactivation and discuss the extent to which the inactive X chromosome may be epigenetically or genetically perturbed in breast cancer.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Chromatin; Development; Epigenetics; X-chromosome inactivation

Mesh:

Year:  2014        PMID: 24937141     DOI: 10.1016/j.febslet.2014.06.023

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  56 in total

1.  Molecular signatures of X chromosome inactivation and associations with clinical outcomes in epithelial ovarian cancer.

Authors:  Stacey J Winham; Nicholas B Larson; Sebastian M Armasu; Zachary C Fogarty; Melissa C Larson; Brian M McCauley; Chen Wang; Kate Lawrenson; Simon Gayther; Julie M Cunningham; Brooke L Fridley; Ellen L Goode
Journal:  Hum Mol Genet       Date:  2019-04-15       Impact factor: 6.150

Review 2.  Sex disparities matter in cancer development and therapy.

Authors:  Sue Haupt; Franco Caramia; Sabra L Klein; Joshua B Rubin; Ygal Haupt
Journal:  Nat Rev Cancer       Date:  2021-04-20       Impact factor: 60.716

3.  New Advances in Human X chromosome status from a Developmental and Stem Cell Biology.

Authors:  Benjamin Patterson; Yoshiaki Tanaka; In-Hyun Park
Journal:  Tissue Eng Regen Med       Date:  2017-11-22       Impact factor: 4.169

4.  Effect of dC → d(m5C) substitutions on the folding of intramolecular triplexes with mixed TAT and C+GC base triplets.

Authors:  Carolyn E Carr; Rajkumar Ganugula; Ronald Shikiya; Ana Maria Soto; Luis A Marky
Journal:  Biochimie       Date:  2017-12-24       Impact factor: 4.079

5.  Targeted next-generation sequencing of cancer genes identified frequent TP53 and ATRX mutations in leiomyosarcoma.

Authors:  Ching-Yao Yang; Jau-Yu Liau; Wei-Ju Huang; Yu-Ting Chang; Ming-Chu Chang; Jen-Chieh Lee; Jia-Huei Tsai; Yi-Ning Su; Chia-Cheng Hung; Yung-Ming Jeng
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

Review 6.  The Role of Xist in X-Chromosome Dosage Compensation.

Authors:  Anna Sahakyan; Yihao Yang; Kathrin Plath
Journal:  Trends Cell Biol       Date:  2018-06-14       Impact factor: 20.808

7.  Sexual Inequality in the Cancer Cell.

Authors:  Arthur P Arnold; Christine M Disteche
Journal:  Cancer Res       Date:  2018-10-01       Impact factor: 12.701

8.  Involvement of X-chromosome Reactivation in Augmenting Cancer Testis Antigens Expression: A Hypothesis.

Authors:  Chang Liu; Bin Luo; Xiao-Xun Xie; Xing-Sheng Liao; Jun Fu; Ying-Ying Ge; Xi-Sheng Li; Gao-Shui Guo; Ning Shen; Shao-Wen Xiao; Qing-Mei Zhang
Journal:  Curr Med Sci       Date:  2018-03-15

9.  An integrative approach to assess X-chromosome inactivation using allele-specific expression with applications to epithelial ovarian cancer.

Authors:  Nicholas B Larson; Zachary C Fogarty; Melissa C Larson; Kimberly R Kalli; Kate Lawrenson; Simon Gayther; Brooke L Fridley; Ellen L Goode; Stacey J Winham
Journal:  Genet Epidemiol       Date:  2017-11-08       Impact factor: 2.135

10.  Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy.

Authors:  Hideki Nakasone; Mats Remberger; Lu Tian; Petter Brodin; Bita Sahaf; Fang Wu; Jonas Mattsson; Robert Lowsky; Robert Negrin; David B Miklos; Everett Meyer
Journal:  Haematologica       Date:  2015-08-06       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.